Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados ArchiMer (1) Electron. J. Biotechnol. (1) Autor Berthou, Christian (1) Berthou,Christian (1) Boisset, Claire (1) Boisset,Claire (1) Bordron, Anne (1) Bordron,Anne (1) Courtois, Anthony (1) Courtois,Anthony (1) Gac Breton, Stephanie (1) Gac-Breton,Stéphanie (1) Guezennec, Jean (1) Guézennec,Jean (1) Mais... Palavra-chave 3)Gal epitope immunogenic oligosaccharide immunotherapy non-Hodgkin lymphoma xenoantigen (2) Complement system Gal alpha(1 -> (1) Complement system Gala(1&rarr (1) Tipo do documento Journal article (1) Text (1) Ano 2012 (2) País Chile (1) France (1) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Complement dependent cytotoxicity activity of therapeutic antibody fragments is acquired by immunogenic glycan coupling Electron. J. Biotechnol. Courtois,Anthony; Gac-Breton,Stéphanie; Berthou,Christian; Guézennec,Jean; Bordron,Anne; Boisset,Claire. Oligosaccharides are implicated in the development of the immune response notably in complement activation. Anti-tumoural immunotherapy by monoclonal antibodies (mAbs) offers some advantages to chemotherapy including cell targeting but some of them are inefficient to generate cytotoxicity dependent complement (CDC) known to be important in the antibody’s efficacy. The aim of this study is to give a CDC activity of mAb by linkage of a complement activating oligosaccharide to this antibody via a hetero-bifunctional linker allowing control of the conjugation reaction. We worked on non Hodgkin Burkitt’s lymphoma as cancer source, Fab fragments of rituximab devoid of complement activity as mAb and the trisaccharide... Tipo: Journal article Palavras-chave: Complement system Gala(1→ 3)Gal epitope immunogenic oligosaccharide immunotherapy non-Hodgkin lymphoma xenoantigen. Ano: 2012 URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-34582012000500005 Complement dependent cytotoxicity activity of therapeutic antibody fragments is acquired by immunogenic glycan coupling ArchiMer Courtois, Anthony; Gac Breton, Stephanie; Berthou, Christian; Guezennec, Jean; Bordron, Anne; Boisset, Claire. Oligosaccharides are implicated in the development of the immune response notably in complement activation. Anti-tumoural immunotherapy by monoclonal antibodies (mAbs) offers some advantages to chemotherapy including cell targeting but some of them are inefficient to generate cytotoxicity dependent complement (CDC) known to be important in the antibody's efficacy. The aim of this study is to give a CDC activity of mAb by linkage of a complement activating oligosaccharide to this antibody via a hetero-bifunctional linker allowing control of the conjugation reaction. We worked on non Hodgkin Burkitt's lymphoma as cancer source, Fab fragments of rituximab devoid of complement activity as mAb and the trisaccharide Gal alpha(1 -> 3)Gal beta(1 -> 4)GlcNAc... Tipo: Text Palavras-chave: Complement system Gal alpha(1 ->; 3)Gal epitope immunogenic oligosaccharide immunotherapy non-Hodgkin lymphoma xenoantigen. Ano: 2012 URL: http://archimer.ifremer.fr/doc/00125/23599/21423.pdf Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco